BioTuesdays

Giving healthcare companies and their stories the exposure they deserve.

 
 

Inventiva targeting MASH at its biological roots

Inventiva (Euronext Paris and Nasdaq: IVA) is advancing development of an oral treatment for metabolic dysfunction-associated steatohepatitis (MASH) with its investigational next-generation pan-peroxisome proliferator...

More Feature Articles

NEWS

Read more

Just a few of the companies we’ve highlighted along the way